Bioquímica y Biología Molecular
Departamento
University Hospital of Zurich
Zúrich, SuizaPublicaciones en colaboración con investigadores/as de University Hospital of Zurich (20)
2023
-
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)
Leukemia
-
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
Leukemia, Vol. 37, Núm. 2, pp. 339-347
2021
-
Biologicals in atopic disease in pregnancy: An EAACI position paper
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 71-89
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 90-113
2020
-
Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie
Allergologie, Vol. 43, Núm. 7, pp. 255-271
-
Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019
Allergy: European Journal of Allergy and Clinical Immunology
-
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774
-
Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2445-2476
-
State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 4, pp. 746-760
-
Type 2 immunity in the skin and lungs
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 7, pp. 1582-1605
2019
-
Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 3, pp. 432-448
2018
-
Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
Allergo Journal International, Vol. 27, Núm. 8, pp. 245-255
2017
-
Altered fatty acid metabolism and reduced stearoyl-coenzyme a desaturase activity in asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 11, pp. 1744-1752
2016
2015
-
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 70, Núm. 7, pp. 727-754
2014
-
Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 69, Núm. 9, pp. 1162-1170
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544